1.Recent Progress on Branched-Chain Amino Acids in Obesity, Diabetes, and Beyond
Md Abu Bakkar SIDDIK ; Andrew C SHIN
Endocrinology and Metabolism 2019;34(3):234-246
Branched-chain amino acids (BCAAs) are essential amino acids that are not synthesized in our body; thus, they need to be obtained from food. They have shown to provide many physiological and metabolic benefits such as stimulation of pancreatic insulin secretion, milk production, adipogenesis, and enhanced immune function, among others, mainly mediated by mammalian target of rapamycin (mTOR) signaling pathway. After identified as a reliable marker of obesity and type 2 diabetes in recent years, an increasing number of studies have surfaced implicating BCAAs in the pathophysiology of other diseases such as cancers, cardiovascular diseases, and even neurodegenerative disorders like Alzheimer's disease. Here we discuss the most recent progress and review studies highlighting both correlational and potentially causative role of BCAAs in the development of these disorders. Although we are just beginning to understand the intricate relationships between BCAAs and some of the most prevalent chronic diseases, current findings raise a possibility that they are linked by a similar putative mechanism.
Adipogenesis
;
Alzheimer Disease
;
Amino Acids, Branched-Chain
;
Amino Acids, Essential
;
Cardiovascular Diseases
;
Chronic Disease
;
Heart Failure
;
Insulin
;
Metabolism
;
Milk
;
Neurodegenerative Diseases
;
Obesity
;
Sirolimus
2.Second Asian Consensus on Irritable Bowel Syndrome
Kok Ann GWEE ; Sutep GONLACHANVIT ; Uday C GHOSHAL ; Andrew S B CHUA ; Hiroto MIWA ; Justin WU ; Young Tae BAK ; Oh Young LEE ; Ching Liang LU ; Hyojin PARK ; Minhu CHEN ; Ari F SYAM ; Philip ABRAHAM ; Jose SOLLANO ; Chi Sen CHANG ; Hidekazu SUZUKI ; Xiucai FANG ; Shin FUKUDO ; Myung Gyu CHOI ; Xiaohua HOU ; Michio HONGO
Journal of Neurogastroenterology and Motility 2019;25(3):343-362
BACKGROUND/AIMS: There has been major progress in our understanding of the irritable bowel syndrome (IBS), and novel treatment classes have emerged. The Rome IV guidelines were published in 2016 and together with the growing body of Asian data on IBS, we felt it is timely to update the Asian IBS Consensus. METHODS: Key opinion leaders from Asian countries were organized into 4 teams to review 4 themes: symptoms and epidemiology, pathophysiology, diagnosis and investigations, and lifestyle modifications and treatments. The consensus development process was carried out by using a modified Delphi method. RESULTS: Thirty-seven statements were developed. Asian data substantiate the current global viewpoint that IBS is a disorder of gut-brain interaction. Socio-cultural and environmental factors in Asia appear to influence the greater overlap between IBS and upper gastrointestinal symptoms. New classes of treatments comprising low fermentable oligo-, di-, monosacharides, and polyols diet, probiotics, non-absorbable antibiotics, and secretagogues have good evidence base for their efficacy. CONCLUSIONS: Our consensus is that all patients with functional gastrointestinal disorders should be evaluated comprehensively with a view to holistic management. Physicians should be encouraged to take a positive attitude to the treatment outcomes for IBS patients.
Anti-Bacterial Agents
;
Asia
;
Asian Continental Ancestry Group
;
Consensus
;
Constipation
;
Diagnosis
;
Diarrhea
;
Diet
;
Epidemiology
;
Gastrointestinal Diseases
;
Humans
;
Intestines
;
Irritable Bowel Syndrome
;
Life Style
;
Methods
;
Probiotics